Home › Research › Biomarkers
Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease
Dincer A, Gordon BA, Hari-Raj A, Keefe SJ, Flores S, McKay NS, Paulick AM, Shady Lewis KE et al.. NeuroImage. Clinical, 2020-11-05
Topic: Amyloid, tau and blood-test diagnosis
Defining a signature of cortical regions of interest preferentially affected by Alzheimer disease (AD) pathology may offer improved sensitivity to early AD compared to hippocampal volume or mesial temporal lobe alone. We found the optimal cortical signature maps were sensitive to early increases in amyloid for the asymptomatic individuals within their respective cohorts and were significant beyond the inclusion of hippocampus volume, but the cortical signature maps performed poorly when analyzing across cohorts. These results suggest the cortical signature maps are a useful MRI biomarker of early AD-related neurodegeneration in preclinical individuals and the pattern of decline differs between LOAD and ADAD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dincer, A., Gordon, B. A., Hari-Raj, A., Keefe, S. J., Flores, S., McKay, N. S., et al. (2020). Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage. Clinical. https://doi.org/10.1016/j.nicl.2020.102491
Vancouver
Dincer A, Gordon BA, Hari-Raj A, Keefe SJ, Flores S, McKay NS, et al. Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage. Clinical. 2020. doi:10.1016/j.nicl.2020.102491. PMID: 33395982.
BibTeX
@article{dincer2020-33395982,
author = {Dincer, A. and Gordon, B. A. and Hari-Raj, A. and Keefe, S. J. and Flores, S. and McKay, N. S. and Paulick, A. M. and Shady Lewis, K. E. and others},
title = {{Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease}},
journal = {NeuroImage. Clinical},
year = {2020},
doi = {10.1016/j.nicl.2020.102491},
pmid = {33395982},
url = {https://doi.org/10.1016/j.nicl.2020.102491}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Defining a signature of cortical regions of interest preferentially affected by Alzheimer disease (AD) pathology may offer improved sensitivity to early AD compared to hippocampal volume or mesial temporal lobe alone.
- We found the optimal cortical signature maps were sensitive to early increases in amyloid for the asymptomatic individuals within their respective cohorts and were significant beyond the inclusion of hippocampus volume, but the cortical signature maps performed poorly when analyzing across cohorts.
- These results suggest the cortical signature maps are a useful MRI biomarker of early AD-related neurodegeneration in preclinical individuals and the pattern of decline differs between LOAD and ADAD.
Why it matters
Cortical signature maps on MRI were sensitive to early amyloid increases in asymptomatic individuals within their own cohorts but performed poorly across late-onset and autosomal dominant Alzheimer disease cohorts. This suggests the pattern of early brain change differs between these forms of the disease, but it is an imaging finding and not a treatment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants588
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (NeuroImage. Clinical) |
| Journal's citation record | 1 / 4 | NeuroImage Clinical: journal h-index 133 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 588 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 34 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.2 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 3 / 6 | Cited 3.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 1 / 4 | Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Tammie L.S. Benzinger: h-index 98 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 31 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33395982) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 30.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Biomarkers
Also in Biomarkers
150 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.